Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 289–310 of 310
ULK1 Restores Cellular Cleanup in Alzheimer's Models
Elevated ULK1 expression enhances autophagy and mitophagy pathways, reducing amyloid and tau accumulation while delaying cognitive decline in Alzheimer's models. This positions cellular cleanup mechanisms as a direct target for disease modification rather than symptomatic management.
Cognition Therapeutics reports Zervimesine slows NPI decline in DLB
Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.
Multi-tissue transcriptomic aging atlas reveals predictive aging biomarkers in the killifish
Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.
AI-Designed TNIK Inhibitor Targets Aging in Pulmonary Fibrosis
Insilico Medicine's rentosertib, an AI-designed TNIK inhibitor discovered through aging-biology-informed target identification, has advanced to Phase III trials for idiopathic pulmonary fibrosis. The program demonstrates that computational drug discovery combined with geroscience principles can identify therapeutically relevant targets overlooked by conventional approaches.
Transposon’s $22m ARPA-H award to test aging-fighting drug
Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.
XPRIZE Healthspan: Functional Recovery Trials Begin
XPRIZE Healthspan has advanced 20 finalists to clinical trials within its $101 million competition, with ten teams receiving $1 million each to test interventions targeting age-related decline in muscle, cognitive, and immune function. The transition from preclinical promise to coordinated human trials represents a critical inflection point: therapeutic mechanisms now must demonstrate measurable functional restoration in adults aged 50–90 within one year.
Aging‐Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
20/20 BioLabs expands longevity test with kidney risk tech
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.
Endlyz raises Seed 2 financing, leans into root-cause neuroscience
Endlyz Therapeutics is pursuing disease modification in Parkinson's by targeting lysosomal dysfunction at the cellular level, addressing the root cause of neurodegeneration rather than managing symptoms. This approach represents a shift toward interventions that could slow disease progression before irreversible damage accumulates.
Acorn Biolabs treats first patients in randomized hair regeneration trial
Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.
PrimeGen US to merge with DT Cloud Star in $1.5B SPAC deal
PrimeGen US, a regenerative medicine company developing stem cell and exosome therapies, is merging with a SPAC at a $1.5 billion valuation to advance clinical trials for acute liver injury and related conditions. The capital infusion targets acceleration of regulatory pathways and commercialization of cell-based treatments grounded in two decades of proprietary stem cell research.
Genflow reveals early data from SIRT6 gene therapy trial in dogs
Genflow's SIRT6 gene therapy demonstrated superior survival and functional improvements in aged beagles across multiple endpoints, including muscle preservation, frailty reduction, and quality of life measures. This interim data from a proof-of-concept trial establishes preliminary evidence that SIRT6 activation may mitigate age-related functional decline, with potential implications for human therapeutic development.
Role of Succinate Dehydrogenase in Age‐Related Th17 Inflammation
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.
Dual-pathway obesity therapy amplifies weight loss and metabolic resilience
OrsoBio's mitochondrial protonophore TLC-6740 produced an additional 4.5% weight loss when combined with tirzepatide, alongside improvements in insulin sensitivity and liver health, while demonstrating safety comparable to GLP-1 monotherapy. The approach targets energy expenditure rather than appetite suppression, representing a shift toward dual-pathway obesity treatment and metabolic resilience optimization.
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Multi-target ALS therapy targets inflammation and oxidative stress
NeuroSense has secured a South Korean patent for PrimeC, an oral combination therapy targeting neuroinflammation and oxidative stress in ALS, extending intellectual property protection through 2042. Phase 2b data demonstrated disease progression slowing and survival benefit, positioning the candidate for pivotal Phase 3 trials.
BioAge reports positive Phase 1 data for BGE-102
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
Lysoway begins Phase 1 trial for neurodegenerative disease treatment
Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.
BioAge Labs Provides Business Updates
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
United Therapeutics receives RMAT designation for Miroliver ELAP
United Therapeutics received FDA Regenerative Medicine Advanced Therapy designation for Miroliver ELAP, a bioengineered external liver assist device combining a decellularized porcine scaffold seeded with human endothelial and hepatic cells. This designation accelerates development of a bridge therapy for acute liver failure, where 30% of patients currently die due to organ shortage despite potential for spontaneous recovery.
Voyager pushes IV gene therapy for Alzheimer’s
Voyager Therapeutics has demonstrated that engineered gene therapies can reach the brain via intravenous infusion rather than invasive delivery, with preclinical data showing VY1706 achieved safe, predictable distribution to the central nervous system in non-human primates. This addresses a fundamental bottleneck in neurological drug development and positions tau-silencing approaches as candidates for clinical translation in Alzheimer's disease.
Gut Luminal Exosomes in Young and Old Mice: Multi‐Omic Characteristics and Regulation of Gut Permeability
Exosomes in the gut lumen change composition with age, with those from older mice directly impairing barrier integrity and insulin sensitivity in younger recipients, while young exosomes reverse these effects in older mice. This identifies a specific molecular mechanism linking intestinal barrier dysfunction to metabolic aging.